Obesity and the Endocannabinoid System: Circulating Endocannabinoids and Obesity

Current Obesity Reports

Volumn 1, Issue 4, 2012, Pages 229-235

  Matias, Isabelle ^a,b   Gatta Cherifi, Blandine ^a,b,c   Cota, Daniela ^a,b  

^a INSTITUT FRANÇOIS MAGENDIE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Cerebrospinal fluid; Circulating endocannabinoids; Food intake; Obesity; Plasma; Quantification; Saliva; Weight loss

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADIPONECTIN; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; GHRELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N OLEOYLETHANOLAMINE; PEPTIDE YY; TRIACYLGLYCEROL;

AGE; BINGE EATING DISORDER; BODY MASS; FEEDING BEHAVIOR; FOOD INTAKE; GENDER; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 85055223478     PISSN: None     EISSN: 21624968     Source Type: Journal    
DOI: 10.1007/s13679-012-0027-6     Document Type: Review

References (45)

1. Smyth S, Heron A. Diabetes and obesity: the twin epidemics. Nat Med. 2006;12: 75-80.
2. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5: 919-31.
3. Sandoval DA, Obici S, Seeley RJ. Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov. 2009;8(5): 386-98.
4. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378: 182-97.
5. Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 2012;26: 114-24.
6. Quarta C, Mazza R, Obici S, et al. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med. 2011;17: 518-26.
7. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3: 771-84.
8. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol Sci. 2004;25: 59-61.
9. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112: 423-31.
10. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28: 640-8.
11. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res. 2009;60: 77-84.
12. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14: 923-30.
13. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296: 678-82.
14. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18: 27-37.
15. Zoerner AA, Gutzki FM, Batkai S, et al. Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: a comprehensive review from an analytical and biological perspective. Biochim Biophys Acta. 2011;1811: 706-23.
16. • Fanelli F, Di Lallo VD, Belluomo I, et al. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res. 2012;53: 481-93. The authors established the reference intervals for circulating endocannabinoids in 121 healthy normal weight subjects.
17. • Gatta-Cherifi B, Matias I, Vallée M, et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes. 2012;36: 880-5. This article illustrates the relationship between feeding status and plasma endocannabinoid levels.
18. Zoerner AA, Batkai S, Suchy MT, et al. UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;883: 161-71.
19. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55: 3053-60.
20. Gorzalka BB, Dang SS. Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology. 2012;153: 1016-24.
21. Paradisi A, Oddi S, Maccarrone M. The endocannabinoid system in ageing: a new target for drug development. Curr Drug Targets. 2006;7: 1539-52.
22. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 2005;30: 1216-21.
23. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54: 2838-43.
24. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91: 3171-80.
25. Matias I, Gonthier MP, Petrosino S, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol. 2007;152: 676-90.
26. Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes. 2007;31: 692-9.
27. • Di Marzo V, Verrijken A, Hakkarainen A, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol. 2009;161: 715-22. This article illustrates the inverse relationship between insulin sensitivity and endocannabinoids levels in humans.
28. Kopelman PG. Obesity as a medical problem. Nature. 2000;404: 635-43.
29. Quercioli A, Pataky Z, Vincenti G, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J. 2011;32: 1369-78.
30. Jumpertz R, Wiesner T, Blüher M, et al. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea-specific role of oleoylethanolamide. Exp Clin Endocrinol Diabetes. 2010;118: 591-5.
31. • Jumpertz R, Guijarro A, Pratley RE, et al. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab. 2011;96: 787-91. The investigators demonstrated an opposite correlation between paired CSF and plasma endocannabinoids with metabolic markers.
32. • Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G et al.: Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One. 2012;7: e42399. The investigators demonstrated that endocannabinoids are quantifiable in human saliva.
33. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes. 2005;29: 755-9.
34. Bordicchia M, Battistoni I, Mancinelli L, et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism. 2010;59: 734-41.
35. Baye TM, Zhang Y, Smith E, et al. Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index. Pharmacogenomics. 2008;9: 1647-56.
36. Aberle J, Flitsch J, Beck NA, et al. Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes. Mol Genet Metab. 2008;95: 188-91.
37. • Sipe JC, Scott TM, Murray S, et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS One. 2010;20(1): e8792. This study demonstrated an association between severe obesity, FAAH polymorphism and plasma endocannabinoids levels.
38. Engeli S, Heusser K, Janke J, et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. Obesity. 2008;16: 1135-7.
39. Di Marzo V, Côté M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia. 2009;52: 213-7.
40. Artmann A, Petersen G, Hellgren LI, et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta. 2008;1781: 200-12.
41. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22: 9612-7.
42. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136: 550-7.
43. Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF. Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab. 2010;7: 49.
44. • Monteleone P, Piscitelli F, Scognamiglio P, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab. 2012;97(6): E917-24. The investigators evaluated the relationship between hedonic eating and plasma endocannabinoids levels.
45. Yoshida R, Ohkuri T, Jyotaki M, et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci U S A. 2010;107: 935-9.